{"id":"envacgen","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions (pain, erythema, swelling)"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Myalgia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a protein subunit vaccine, Envacgen presents recombinant antigens to the immune system to generate both humoral and cellular immune responses. The vaccine is formulated to enhance immunogenicity and promote protective immunity against its target pathogen or disease. This approach avoids the use of live or attenuated organisms, offering a safer vaccine platform.","oneSentence":"Envacgen is a recombinant protein subunit vaccine designed to stimulate immune responses against specific disease targets through antigen presentation.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:11:02.142Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"COVID-19 prevention (protein subunit vaccine candidate)"}]},"trialDetails":[{"nctId":"NCT07178522","phase":"PHASE3","title":"A Study to Evaluate the Immunogenicity and Safety of an EV71 Vaccine (Envacgen®) in Children Aged 6 to <10 Years Compared to Children Aged 2 to <6 Years","status":"RECRUITING","sponsor":"Medigen Vaccine Biologics Corp.","startDate":"2025-06-25","conditions":"Enterovirus 71 Inactivated Vaccine","enrollment":378}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Envacgen®","genericName":"Envacgen®","companyName":"Medigen Vaccine Biologics Corp.","companyId":"medigen-vaccine-biologics-corp","modality":"Biologic","firstApprovalDate":"","aiSummary":"Envacgen is a recombinant protein subunit vaccine designed to stimulate immune responses against specific disease targets through antigen presentation. Used for COVID-19 prevention (protein subunit vaccine candidate).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}